Astellas links with Sanwa to strengthen hand in renal disease field
This article was originally published in Scrip
Astellas is looking to strengthen its commercial capabilities in the renal disease area through a two-product cross-promotion alliance with Sanwa Kagaku Kenkyusho in Japan for mineral disorders in renal disease patients.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.